ASCO 2026 Review – A Smarter, More Selective, and Personalized New Era in Oncology
What made ASCO 2026 important was not only the number of positive phase 3 results. The striking point was that two seemingly opposite strategies were strengthened at the same time. This is not a contradiction; it is the genuine maturation of personalized oncology.
⬆ TREATMENT INTENSIFICATION
In carefully selected, biologically high-risk patients, integrating systemic therapy earlier and more aggressively.
PROTEUS · RASolute 302 · frontMIND · HARMONi-6 · KEYNOTE-B15/EV-304 · LIBRETTO-432 · EMERALD-3 · MATTERHORN
⬇ DE-ESCALATION
In well-selected patients, reducing unnecessary surgery/chemo/RT burden while preserving the same cancer control with better quality of life.
SENOMAC · OPTIMA · CIRCULATE/GALAXY/ALTAIR · FASTRACK II · SERENA-6 · ARACOG
Going forward, decisions will rest not only on tumor stage, but on tumor biology, genomic risk, MRD/ctDNA status, treatment response, the patient's functional status, quality-of-life goals, and the drug's access/regulatory status.
How to read this review
This piece reads the ~50 standout studies and themes from ASCO 2026 not as isolated news items but within large axes of clinical transformation. Some studies were published simultaneously in peer-reviewed journals; others are abstract, company announcement, or press-program level. Evidence levels therefore differ — and this distinction is deliberately preserved throughout.
The showcase of ASCO 2026 was a cluster of large phase 3 trials. Though in different cancers, they shared a common thread: they forced a rethink of the standard-of-care paradigm.
| Study | Cancer type | Key data | Clinical meaning | Evidence / caution |
|---|---|---|---|---|
| RASolute 302 | Previously treated metastatic pancreatic adenocarcinoma | n=500; OS 13.2 vs 6.7 mo (HR 0.40); PFS 7.3 vs 3.5 mo (HR 0.45); ORR 33.2% vs 11.8% | RAS targeting reaches very strong phase 3 survival data in pancreatic cancer for the first time | PRACTICE-CHANGING Phase 3, NEJM; FDA Expanded Access opened |
| PROTEUS | High-risk localized/locally advanced prostate | n=2,109; pCR/MRD 8.9% vs 1.0%; 5-yr MFS 78.2% vs 73.5% (HR 0.80); EFS HR 0.71 | Perioperative intensification with apalutamide + ADT around radical prostatectomy | CANDIDATE STANDARD Phase 3, NEJM; OS maturity awaited |
| frontMIND | Newly diagnosed high-risk DLBCL/HGBL | Tafasitamab + lenalidomide + R-CHOP; PFS HR 0.75; 3-yr PFS 67.3% vs 60.7% | Strengthening the R-CHOP backbone in high-risk aggressive B-cell lymphoma | CANDIDATE STANDARD Phase 3; OS and subgroups to watch |
| HARMONi-6 | Advanced squamous NSCLC (1st line) | n=532; ivonescimab+chemo vs tislelizumab+chemo; OS 27.9 vs 23.7 mo (HR 0.66); PD-L1-independent | PD-1/VEGF bispecific shows strong signal in squamous lung cancer | CANDIDATE STANDARD Phase 3; double-blind, China-based — generalizability with caution |
| LIBRETTO-432 | RET fusion+ resected stage IB-IIIA NSCLC | Adjuvant selpercatinib; EFS HR 0.172; median EFS not reached vs 31.8 mo; 24-mo EFS 91.5% vs 61.1% | Expands the scope of molecular adjuvant therapy in early-stage disease | PRACTICE-CHANGING Phase 3, NEJM; toxicity balance to watch |
| KEYNOTE-942/V940 | Resected high-risk melanoma | At 5-yr follow-up, recurrence/death risk reduced 49%, distant metastasis/death 59% | Personalized mRNA neoantigen vaccine + pembrolizumab maintains its long-term signal | TO WATCH Long-term phase 2b; phase 3 (V940-001) ongoing |
| SENOMAC | Early breast, 1-2 positive sentinel nodes | Omitting ALND did not compromise long-term survival; quality of life preserved | Important phase 3 data reinforcing axillary surgical de-escalation | PRACTICE-CHANGING Phase 3; patient selection, RT field critical |
| ROADS | Large brain metastasis resection | Implanted "tile-based" radiation/brachytherapy promising for local control and QoL | May reshape post-surgical local radiation strategies | TO WATCH LBA; detailed publication and long-term neurocognitive data awaited |
Pancreatic cancer is one of the hardest areas in modern oncology. In metastatic disease, options after first-line chemotherapy are limited and second-line treatments usually add little to survival. For this reason, the difference shown by RASolute 302 should be read as historic not only for pancreatic cancer but for the druggability of RAS biology itself — because oncogenic RAS is present in over 90% of PDAC cases and was considered an "undruggable target" for decades.
RASOLUTE 302 — TRIAL DETAILS
- Design: Global, randomized, open-label phase 3; 500 patients (ECOG 0-1), 59 sites (North America, Europe, Asia). Metastatic PDAC after one prior line of chemotherapy.
- Randomization (1:1): Oral daraxonrasib 300 mg/day vs investigator's choice of one of 4 standard chemotherapy regimens.
- Dual primary endpoints: OS and BICR-assessed PFS in the RAS G12-mutant population.
- Efficacy: OS 13.2 vs 6.7 mo (HR 0.40 — ~60% reduction in death risk); PFS 7.3 vs 3.5 mo (HR 0.45); ORR 33.2% vs 11.8%. Significant in both RAS G12-mutant and overall populations (PFS HR ~0.45 and ~0.49 — activity beyond mutation selectivity).
- Safety — a striking difference: Grade ≥3 treatment-related AEs 43.6% vs 57.5%; serious AEs 10.8% vs 18.7%; discontinuation due to AEs only 1.2% vs 11.2%. Main AEs: rash and stomatitis. Time to deterioration in pain and quality of life was delayed (HR ~0.51 and ~0.60).
- Publication: O'Reilly EM, Wainberg ZA, Wolpin BM, et al. NEJM, May 31, 2026, DOI 10.1056/NEJMoa2605555 (ASCO Plenary, Abstract LBA5).
What is a RAS(ON) inhibitor?
RAS proteins are central hubs of cell growth signaling; in cancer they can remain constitutively active ("ON"). Daraxonrasib is an oral, multi-selective "tri-complex" inhibitor that targets the active GTP-bound RAS(ON) state broadly — not a single KRAS subtype — covering variants such as G12D, G12V, G12R (and partly wild-type RAS).
Important regulatory note
Daraxonrasib has very strong phase 3 data but is not yet fully FDA-approved; the FDA has opened Expanded Access, and data are being submitted for approval. The correct framing for patients: "a very strong candidate new standard; routine access depends on country approvals."
How to intensify treatment in early-stage disease was a major theme at ASCO 2026. The core logic: if a patient is biologically high-risk, integrating systemic therapy earlier — before metastasis develops — may change long-term outcome. The critical nuance here is that benefit must be balanced against toxicity burden — especially in LIBRETTO-432.
| Study | Disease | Strategy | What changes? | Caution |
|---|---|---|---|---|
| PROTEUS | High-risk localized/locally advanced prostate | Neoadjuvant + adjuvant apalutamide + ADT + radical prostatectomy | Perioperative systemic intensification as a candidate new standard | Increased rash, rare treatment-related deaths, OS maturity; patient selection to be clarified |
| LIBRETTO-432 | RET fusion+ early-stage NSCLC | Adjuvant selpercatinib | After EGFR/ALK, RET enters the adjuvant molecular space; EFS HR 0.172 very strong | Grade ≥3 AEs 66.7% (placebo 23.7%); discontinuation 17.3%; ALT/AST elevation, hypertension — benefit/toxicity balance to watch |
| MATTERHORN | Resectable gastric/GEJ adenocarcinoma | Perioperative durvalumab + FLOT | Perioperative immunotherapy as standard in gastric cancer; 2026 surgical-feasibility analyses supportive | PD-L1/MSI subgroup effect and surgical safety details important |
| KEYNOTE-B15/EV-304 | Muscle-invasive bladder cancer | Perioperative enfortumab vedotin + pembrolizumab | Chemo-immuno/ADC combinations move into the neoadjuvant space | EV toxicity (neuropathy, skin, hyperglycemia), patient selection, surgical timing critical |
One of the most important philosophical themes at ASCO 2026 was de-escalation. De-escalation does not mean undertreating; in well-selected patients, it means reducing unnecessary surgery, chemotherapy, or radiotherapy burden — based on scientific evidence — while preserving the same cancer control with better quality of life. The shared message: the cost of treatment matters as much as the outcome.
| Area | Study | Key message | Meaning for patients |
|---|---|---|---|
| Axillary surgery | SENOMAC | ALND can be safely omitted in most patients with 1-2 positive sentinel nodes | Lymphedema, shoulder restriction, pain, and QoL loss may decrease |
| Adjuvant chemotherapy | OPTIMA | Omitting chemotherapy in genomically low-risk (Prosigna) is non-inferior (5-yr 93.7% vs 94.9%) | Some clinically high-risk HR+/HER2− patients can be spared chemotherapy |
| Axillary staging | SLNB/cALND-CDK4/6 analyses | More aggressive axillary investigation solely to determine CDK4/6 eligibility seems unjustified | Surgical morbidity vs systemic benefit can be weighed more carefully |
| Primary kidney local therapy | FASTRACK II | SABR is a strong definitive option in inoperable patients; 5-yr local control ~98% | Local control in 1-3 sessions for selected inoperable patients |
| Adjuvant colon cancer | CIRCULATE / ALTAIR / GALAXY | De-escalation in ctDNA/MRD-negative, intensification in positive, gaining strength | Unnecessary chemotherapy may be reduced; high-risk patients caught early |
What is de-escalation?
Not arbitrary reduction of treatment, but using scientific evidence to achieve the same oncologic safety with fewer side effects, less surgical burden, shorter treatment duration, or better quality of life. ASCO 2026 showed de-escalation is no longer a theoretical idea but an active clinical research program across many tumor types.
Breast cancer stood out along two axes at ASCO 2026: new ADC and endocrine strategies in metastatic disease, and precision de-escalation reducing chemotherapy and surgical burden in early disease. OPTIMA (sparing chemotherapy via Prosigna), SENOMAC (ALND omission), and SERENA-6 (using ctDNA to catch ESR1 mutation before radiological progression and switch early from aromatase inhibitor to camizestrant) were the conceptual studies of this area.
| Study | Patient group | Key message | Evidence level |
|---|---|---|---|
| OPTIMA | ER+/HER2− early breast, clinically high-risk | Omitting chemotherapy at low Prosigna risk is non-inferior (5-yr 93.7% vs 94.9%) | PRACTICE-CHANGING |
| SENOMAC | cN0, 1-2 positive sentinel nodes | ALND omission safe long-term; axillary morbidity reduced | PRACTICE-CHANGING |
| SERENA-6 | ESR1-mutant HR+/HER2− advanced breast | Early endocrine switch (camizestrant) via ctDNA improves PFS/PFS2 | CANDIDATE STANDARD |
| ASCENT-04 | PD-L1+ metastatic TNBC, 1st line | Sacituzumab govitecan + pembrolizumab superior PFS vs chemo + pembrolizumab | CANDIDATE STANDARD |
| dato-DXd (TROPION-Breast02) | PD-L1− / IO-ineligible mTNBC | FDA approval (May 22, 2026); PFS 10.8 vs 5.6 mo, OS 23.7 vs 18.7 mo | FDA APPROVED |
| Izalontamab brengitecan | Metastatic TNBC / low-ER subgroups | EGFR×HER3 bispecific ADC drawing attention with PFS/OS signal | TO WATCH |
Lung cancer stood out in several directions. In ALK+ disease, the CROWN 7-year update supported lorlatinib's remarkable durability in long-term disease control. In EGFR exon 20 insertions, WU-KONG28 showed sunvozertinib's first-line superiority over chemotherapy. LIBRETTO-432 expanded adjuvant selpercatinib in early-stage RET+ disease.
| Study | Subgroup | Key data / message | Practical impact |
|---|---|---|---|
| CROWN (7-yr) | ALK+ advanced NSCLC | At 7 years, PFS rate ~55% with lorlatinib; ~3% with crizotinib | Lorlatinib's position as long-term 1st-line standard strengthens |
| WU-KONG28 | EGFR exon 20 ins advanced NSCLC | Sunvozertinib superior antitumor activity vs platinum chemo in 1st line | Chemo-free 1st-line approach strengthens in exon20ins patients |
| LIBRETTO-432 | RET+ resected stage IB-IIIA NSCLC | Adjuvant selpercatinib EFS HR 0.172; 24-mo EFS 91.5% vs 61.1% | RET testing at diagnosis becomes critical in early-stage too |
| AcceleRET-Lung | RET+ advanced NSCLC | Pralsetinib efficacy in 1st line; infection/safety headlines noted | RET-targeted options expand; toxicity management important |
| HARMONi-6 | Squamous advanced NSCLC | Ivonescimab+chemo OS 27.9 vs 23.7 mo (HR 0.66); PD-L1-independent | New competitive arena for PD-1/VEGF bispecific — with China-population nuance |
HARMONi-6 — a critical nuance
Ivonescimab + chemo showed OS 27.9 vs 23.7 mo (HR 0.66; 34% reduction in death risk) and PD-L1-independent benefit vs tislelizumab + chemo — a strong signal for a dual-targeting (PD-1/VEGF) bispecific in squamous NSCLC. However, the trial is a double-blind phase 3 conducted in China; lead investigator Shun Lu himself framed the result explicitly as "a first-line standard in China." Global generalizability requires validation in different populations. It is also historic as the first China-originated oncology drug selected for an ASCO Plenary Session.
| Study | Patient group | Key message | Clinical impact / nuance |
|---|---|---|---|
| RASolute 302 | Previously treated metastatic pancreatic | Daraxonrasib nearly doubled OS (HR 0.40) | The era of RAS targeting begins in pancreatic cancer |
| BREAKWATER | BRAF V600E metastatic CRC | Encorafenib + cetuximab + chemo effective in 1st line | Supports moving BRAF targeting to an earlier line |
| HERIZON-GEA-01 | HER2+ metastatic gastroesophageal | Zanidatamab + chemo ± tislelizumab; OS (tisle arm) 26.4 vs 19.2 mo (HR 0.72) | HER2 targeting beyond trastuzumab; control arm is trastuzumab (not a direct comparison with KEYNOTE-811) |
| HORIZON-CRC01 | HER2+, RAS/RAF WT, refractory CRC | Trastuzumab rezetecan PFS 5.5 vs 2.8 mo; ORR 40.7% vs 4.5% | HER2 ADC space strengthens in CRC |
| EMERALD-3 | Embolization-eligible unresectable HCC | TACE + STRIDE + lenvatinib PFS 13.0 vs 9.8 mo | TACE now considered integrated with systemic therapy |
| CIRCULATE / ALTAIR / GALAXY | MRD/ctDNA in colon cancer | MRD positive/negative distinction strengthens adjuvant decisions | High potential to personalize adjuvant chemotherapy |
| Study | Disease | Key message | Careful interpretation |
|---|---|---|---|
| PROTEUS | High-risk localized/locally advanced prostate | pCR/MRD and MFS gain with apalutamide + ADT (EFS HR 0.71) | Patient selection, toxicity burden, OS maturity important |
| Decipher / genomic classifiers | Prostate cancer | Refine intensification and de-escalation decisions alongside clinical risk | Not a standalone decision tool; multidisciplinary interpretation required |
| ENZAMET (Decipher) | mHSPC | Role of genomic tools in separating docetaxel benefit and prognosis discussed | Predictive/prognostic distinction must be made clearly |
| KEYNOTE-B15/EV-304 | Muscle-invasive bladder | Perioperative EV + pembrolizumab; strong pCR/EFS/OS signal | Neuropathy, skin toxicity, hyperglycemia, surgical timing |
| POTOMAC | BCG-naive high-risk NMIBC | Durvalumab + BCG received FDA approval; core data is DFS superiority | DFS, not OS, context; patient selection and toxicity |
| RAMPART | Post-resection RCC (adjuvant) | Durvalumab ± tremelimumab DFS signal; QoL may be affected early | Careful comparison with adjuvant pembrolizumab (KEYNOTE-564) standard |
| miR-371 / SWOG S1823 | Testis cancer surveillance | High negative predictive value in relapse follow-up; potential to reduce imaging burden | Sensitivity limits and usage algorithm to be clarified |
| Study | Disease | Main approach | Clinical meaning |
|---|---|---|---|
| frontMIND | High-risk DLBCL/HGBL | Tafasitamab + lenalidomide + R-CHOP | Strengthening the R-CHOP backbone in high-risk patients (PFS HR 0.75) |
| SUCCESSOR-2 | Relapsed/refractory multiple myeloma | Mezigdomide + carfilzomib + dexamethasone | New CELMoD (cereblon E3 ligase modulator) class comes to the fore |
| SUNMO | R/R large B-cell lymphoma | Mosunetuzumab + polatuzumab vedotin vs R-GemOx | Bispecific antibody + ADC strengthen the chemotherapy alternative |
| Epcoritamab + mini-CVP | Elderly/unfit DLBCL | Bispecific antibody + low-intensity chemotherapy | Frailty-focused lymphoma therapies gain importance |
| PRMT5 inhibitor | Hodgkin lymphoma (and others) | Early signal for a new epigenetically targeted class | Epigenetic targeting horizon widens in lymphoma |
| CONQUER / CD5 CAR-T | T-ALL / PTCL | CD5-targeted CAR-T | Cellular therapy horizon widens in T-cell malignancies |
| Study | Rare/difficult area | Key data | Practical message |
|---|---|---|---|
| SARC041 | Dedifferentiated liposarcoma | Abemaciclib PFS 9.7 vs 1.5 mo (HR 0.38) | CDK4 targeting finds first positive phase 3 in a rare sarcoma |
| PEAK | Advanced GIST after imatinib | Bezuclastinib + sunitinib PFS 16.5 vs 9.2 mo (HR 0.50) | Dual KIT inhibition may change 2nd-line GIST standard |
| OptimUM-02 | HLA-A2-negative metastatic uveal melanoma | Darovasertib + crizotinib PFS 6.9 vs 3.1 mo; ORR 37.1% vs 5.8% | Strong targeted candidate in the HLA-A2− group beyond tebentafusp |
| FASTRACK II | Inoperable primary kidney cancer | No local recurrence in 70 patients over long follow-up; pooled 5-yr local control ~98% | SABR as definitive local therapy in selected inoperable patients |
| Pivekimab sunirine | Blastic plasmacytoid dendritic cell neoplasm (BPDCN) | New FDA approval for a CD123-targeted ADC | New targeted ADC option in a rare hematologic tumor |
At ASCO 2026, not only drugs but biomarker technologies drew attention. Digital pathology, AI, and spatial tumor-microenvironment analyses are moving biomarkers beyond a "positive/negative" level toward reading the map of the tumor. It is no longer only whether the target is present; it is where the target sits within the tumor, whether immune cells have penetrated, how the stromal barrier behaves, and the location of tumor-infiltrating lymphocytes and tertiary lymphoid structures (TLS).
A PARADIGM SHIFT IN BIOMARKERS
- Old: Is the target present or not? (Is PD-L1 high, HER2 positive, MSI present?)
- New: Where is the target, how dense, with which cells adjacent?
- Microenvironment: Have T cells entered the tumor, is there a stromal barrier, has a TLS formed?
- Decision support: An AI model combines pathology + clinical data for treatment-response and risk prediction.
This area is still mostly at the "to watch / hypothesis-strengthening" level; not a routine practice standard, but one of the strongest directions for the future.
What is spatial profiling?
It analyzes not only the number of cells in a tumor tissue but their positions relative to one another. For example, it asks whether T cells have entered the tumor or remained only at the edge, and how they relate to the vascular and stromal architecture — increasingly important for interpreting immunotherapy response and ADC target expression.
At ASCO 2026, GLP-1 receptor agonists, short-term fasting, exercise, yoga, and weight management were increasingly discussed with scientific data. Quality-of-life-focused studies such as cognitive survivorship (e.g. ARACOG — the difference in blood-brain barrier penetration and cognitive effect between darolutamide and enzalutamide) showed that treatment choice involves not only survival but what kind of survival is lived. Reports of associations between GLP-1 agonists and better survival/lower progression in breast and other cancers are exciting.
The right message for metabolic oncology
Obesity, insulin resistance, diabetes, muscle loss, and inflammation can affect cancer treatment response. However, most GLP-1 data are observational and associational; they do not prove causality. There is no evidence at the level of "let's add GLP-1 to cancer treatment," and no GLP-1 agent is approved for a cancer treatment/prevention indication. Approaches such as peri-chemotherapy short fasting must also be evaluated carefully for sarcopenia, diabetes, nutrition, and patient selection. These are supportive/potentially complementary areas; they do not replace standard treatment.
One of the most important distinctions for patient readers: a drug showing a positive result at a congress does not mean it can be prescribed immediately or is accessible in a given country.
| Agent / approach | Area | Regulatory status | Correct framing for patients |
|---|---|---|---|
| Daraxonrasib | Metastatic pancreatic | Strong phase 3; FDA Expanded Access (not full approval) | Very strong candidate new standard; routine access depends on approvals |
| dato-DXd (Datroway) | PD-L1− mTNBC | FDA-approved (May 22, 2026); NCCN Cat 1; country processes pending | Approved in the US; country access evaluated separately |
| Darovasertib + crizotinib | HLA-A2− uveal melanoma | Not yet FDA-approved; NDA targeted | Promising but in the regulatory process |
| Bezuclastinib + sunitinib | GIST after imatinib | FDA Priority Review process | If approved, could change 2nd-line GIST standard |
| Durvalumab + BCG | BCG-naive high-risk NMIBC | Received FDA approval (POTOMAC) | Now in the clinical-use and access/reimbursement axis |
| NOUS-209 | Cancer prevention in Lynch syndrome | FDA Fast Track (not approval) | A cancer-preventive vaccine candidate; not in routine use |
| Puxitatug samrotecan | B7-H4+ endometrial/ovarian | Phase 1/2a data; phase 3 ongoing | Strong early signal; phase 3 awaited for standard |
HEADLINES THAT CAN BE MISUNDERSTOOD — THE CORRECT FRAMING
- POTOMAC: Should not be written as OS data; should be told in the context of FDA approval and DFS superiority.
- HARMONi-6: OS data strong (HR 0.66); but a double-blind study in China; the lead investigator himself said "standard in China." Global generalizability must be separately validated.
- HERIZON-GEA-01: Control arm is trastuzumab + chemo (not KEYNOTE-811's pembrolizumab + trastuzumab); a direct comparison cannot be made.
- LIBRETTO-432: EFS HR 0.172 very impressive; but grade ≥3 AEs 66.7% and 17.3% discontinuation — the benefit must be presented together with the toxicity burden.
- GLP-1 data: Mostly observational/associational; no inference of causality or "add to routine oncology" should be drawn.
- persevERA / giredestrant: Not HER2+; should be read as an ER+/HER2− oral SERD strategy, together with lidERA and SERENA-6.
- NOUS-209: Fast Track ≠ FDA approval; the headline "a cancer-preventive vaccine has been found" should not be used.
- Amivantamab social-media stories: It is not a vaccine; it is not yet an FDA-approved standard in head and neck cancer.
- SABR / FASTRACK II: It should not be said that it replaced surgery in surgery-eligible patients; it is a strong option for selected inoperable/high-risk patients.
- ROADS, AI/spatial, lifestyle headlines: Not practice-changing; should be positioned as "to watch / hypothesis-strengthening."
PRIORITIES FOR CONTEMPORARY CLINICAL AND ACADEMIC PRACTICE
- 1. Molecular testing at diagnosis: EGFR, ALK, ROS1, RET, MET, HER2, BRAF, MSI, NTRK, HRD — not limited to advanced disease; they also affect early-stage decisions.
- 2. Strengthen MRD/ctDNA infrastructure: MRD-guided decisions will increase in colon, RCC, prostate, testis, and beyond.
- 3. A de-escalation culture: Avoiding unnecessary axillary surgery, chemotherapy, or overtreatment is in the patient's favor.
- 4. Intensify selectively: PROTEUS, KEYNOTE-B15/EV-304, MATTERHORN strengthen early systemic therapy in high risk — toxicity (e.g. LIBRETTO-432) must be balanced.
- 5. State regulatory status clearly: ASCO data, Fast Track, Priority Review, and FDA approval must not be confused.
- 6. Standardize ADC toxicity management: Center algorithms needed for ILD/pneumonitis, cytopenia, neuropathy, skin, GI, and ocular toxicities.
- 7. Immunotherapy toxicity boards: Hepatitis, colitis, endocrinopathy, pneumonitis, neurologic toxicities must be recognized early.
- 8. Digital pathology and AI infrastructure are strategic: Biomarkers will be interpreted together with tumor map and microenvironment.
- 9. Watch rare-tumor phase 3 data: SARC041, PEAK, FASTRACK II, OptimUM-02 can make a big difference in small areas.
- 10. Patient-reported outcomes should be routine: Fatigue, cognitive function (ARACOG), pain, diarrhea, sleep, quality of life should be measured.
- 11. Metabolic health as part of care: Obesity, insulin resistance, diabetes, muscle loss, nutrition — but the evidence level must be conveyed honestly.
- 12. Use the right language of hope: Prefer scientific, calm narration over "miracle," "cancer is over," "a vaccine has been found."
- 13. Expand multidisciplinary boards: Molecular tumor board, MRD board, toxicity board, quality of life — working together.
- 14. Financial and access reality: Beyond whether something is approved, accessibility, reimbursement, and country conditions must be explained.
- 15. Separate fast news from deep analysis: Not every ASCO item must become a review; selected big themes should be covered comprehensively.
🗣 How to explain ASCO 2026 to patients and families
"At ASCO 2026, very important advances were announced for cancer treatment. In some difficult cancers, new targeted drugs extended survival; in some early-stage cancers, reassuring results emerged toward reducing unnecessary treatment. But every new study does not mean standard treatment for everyone. Whether a treatment is right for you must be evaluated according to your cancer type, stage, molecular tests, prior treatments, overall health, and the drug's access status in your country."
⚡ WHY IT MATTERS
The strongest message of ASCO 2026 is that oncology is no longer only a race to develop more powerful drugs. This meeting reminded us to choose treatment more wisely, to intensify at the right time, to de-escalate boldly when appropriate, and to accept the patient's quality of life as an inseparable part of success. RASolute 302 (RAS targeting in pancreatic cancer) and PROTEUS (perioperative intensification in prostate cancer) showed where intensification is meaningful; SENOMAC, OPTIMA, and MRD/ctDNA studies opened the discussion of in which patients less treatment is safe.
✅ STRENGTHS
The meeting backed many positive phase 3 results with simultaneous NEJM/Lancet/JCO publications (RASolute 302, PROTEUS, LIBRETTO-432). Both a breakthrough in "undruggable" targets like oncogenic RAS and the support of de-escalation with mature phase 3 data showed the field maturing in two directions. The entry of biomarkers, MRD, and patient-reported outcomes (including cognitive survivorship) into the main program signals oncology's evolution toward a holistic, beyond-the-tumor view.
⚠️ LIMITATIONS AND CAUTIONS
Evidence levels are not equal: some are mature phase 3/NEJM, others abstract/company announcement. HARMONi-6 is in a China-specific population; HERIZON-GEA-01's control arm is trastuzumab (not a direct comparison with KEYNOTE-811). In many intensification studies, OS has not yet matured (PROTEUS), and the toxicity burden can be serious (LIBRETTO-432: 66.7% grade ≥3). GLP-1 and lifestyle data are observational. "Presented at ASCO" ≠ "approved" ≠ "accessible." Even very strong candidates like daraxonrasib are not yet at the full-approval/reimbursement stage.
🩺 IMPLICATIONS FOR PRACTICE
In contemporary practice, success is not giving every patient the newest treatment; it is determining the right treatment intensity by reading the patient's biology, genomic risk, MRD status, functional status, quality-of-life goals, and access conditions together. Molecular-test and MRD infrastructure, multidisciplinary board structures, and toxicity-management algorithms are the operational backbone of this transformation. Decision trees in pancreatic (RAS), gastric (HER2/perioperative IO), TNBC (TROP2 ADC), and prostate (perioperative) are being updated after this meeting.
❓ QUESTIONS FOR THE FUTURE
When will daraxonrasib receive full FDA approval and country access; will RAS targeting move to the first line and to other RAS-dependent tumors (colorectal, lung)? Will HARMONi-6 be validated in non-China populations? In which tumors will MRD-guided de-escalation become standard? Will the OS data of perioperative intensification (PROTEUS) confirm the PFS/MFS signal? When will spatial/AI biomarkers enter routine decision-making? How will molecular-test and MRD access be brought to the level this personalized era requires?
ASCO 2026 showed three axes strengthening at once. First, biological targets are being drugged more boldly — RAS, RET, HER2, B7-H4, PRAME, CDK4, KIT, CD123 are finding clinical traction across different tumors. Second, treatment intensity in early-stage cancer is being tuned more precisely — perioperative intensification in some patients, surgical/chemotherapy reduction in others. Third, the patient experience is moving to the center of clinical decisions — quality of life, cognitive function, toxicity management, real-world sustainability.
The most important lesson from this meeting is this: the future question in cancer treatment is not only "which drug is more effective?" The real question is: which patient, with which biological risk, benefits most from which treatment, at which intensity, at which quality-of-life cost, and under which access conditions? ASCO 2026 showed that the answers to this question have become more scientific, more data-driven, and more patient-centered. Oncology is moving from the era of "more treatment" to the era of "the right treatment."
References
- O'Reilly EM, Wainberg ZA, Wolpin BM, et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (RASolute 302). NEJM, May 31, 2026. DOI: 10.1056/NEJMoa2605555 (ASCO Plenary, Abstract LBA5).
- Johnson & Johnson. PROTEUS phase 3 results in high-risk localized/locally advanced prostate cancer (EFS HR 0.71; MFS HR 0.80; pCR/MRD 8.9% vs 1.0%). ASCO 2026; simultaneous NEJM.
- ASCO 2026. LIBRETTO-432: adjuvant selpercatinib in resected stage IB-IIIA RET fusion+ NSCLC (EFS HR 0.172; 24-mo EFS 91.5% vs 61.1%). Simultaneous NEJM.
- Lu S, et al. HARMONi-6: ivonescimab + chemotherapy vs tislelizumab + chemotherapy in advanced squamous NSCLC (OS 27.9 vs 23.7 mo, HR 0.66). ASCO 2026 Plenary, Abstract LBA4.
- ASCO 2026. frontMIND: tafasitamab + lenalidomide + R-CHOP in high-risk DLBCL/HGBL (PFS HR 0.75).
- FDA, Oncology Center of Excellence. Datopotamab deruxtecan-dlnk (Datroway) approval for PD-1/PD-L1-ineligible mTNBC, May 22, 2026 (TROPION-Breast02; Dent R et al., Annals of Oncology, April 2026).
- Shitara K, Elimova E, et al. Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer (HERIZON-GEA-01). NEJM 2026;394:2002-2014. (Control arm: trastuzumab + chemo.)
- Merck & Moderna. KEYNOTE-942 / mRNA-4157 (V940) 5-year update. ASCO 2026.
- ASCO Press / Reuters. SENOMAC (axillary de-escalation) and OPTIMA (Prosigna-guided chemotherapy omission, 5-yr 93.7% vs 94.9%). 2026.
- FDA. Durvalumab + BCG approval for high-risk NMIBC (POTOMAC). 2026.
- Pfizer. CROWN 7-year update, lorlatinib in ALK+ NSCLC. ASCO 2026.
- ASCO 2026 abstract database: BREAKWATER, HORIZON-CRC01, EMERALD-3, SARC041, PEAK, OptimUM-02, FASTRACK II, SUCCESSOR-2, SUNMO, WU-KONG28, AcceleRET-Lung, CIRCULATE/ALTAIR/GALAXY, SERENA-6, ASCENT-04, ROADS, ARACOG, ENZAMET-Decipher, miR-371/SWOG S1823, pivekimab sunirine (BPDCN), puxitatug samrotecan, izalontamab brengitecan.
- drozdogan.com. ASCO 2026 preview articles and current oncology assessments archive.
This article is medical news/review and for informational purposes; it does not constitute individual treatment guidance. The evidence levels of studies presented at ASCO 2026 are not equal — some are mature phase 3 data published simultaneously in peer-reviewed journals, others are abstract, company announcement, or interim-analysis level. A drug showing a positive result at a congress does not mean it can be prescribed immediately or is accessible in your country; FDA Fast Track, Priority Review, and full approval are different statuses, and national regulatory approval and reimbursement are evaluated separately. HARMONi-6 is a double-blind study conducted in a Chinese population and its global generalizability must be separately validated; the control arm of HERIZON-GEA-01 is trastuzumab + chemotherapy (it cannot be directly compared with KEYNOTE-811, which contains pembrolizumab + trastuzumab). In LIBRETTO-432, the strong EFS gain must be considered together with a notable toxicity burden (grade ≥3 66.7%). Most GLP-1 and lifestyle data are observational and do not prove causality. Patients should always evaluate treatment decisions with their own oncologists, in light of individual disease characteristics and current approval status. All data were verified from official ASCO 2026 presentations and abstracts, simultaneous NEJM/Lancet/JCO publications, FDA approval notices, and relevant institutional/company announcements.
